Compare
Alto Neuroscience, Inc. vs Lexicon Pharmaceuticals, Inc. vs Fortress Biotech, Inc. vs Benitec Biopharma Inc.
| Latest fiscal year | Alto Neuroscience, Inc. ANRO | Lexicon Pharmaceuticals, Inc. LXRX | Fortress Biotech, Inc. FBIO | Benitec Biopharma Inc. BNTC |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2026-06-30 |
| Revenue | n/a | $49.80M | $63.26M | n/a |
| Revenue growth (YoY) | n/a | +60.2% | +9.7% | n/a |
| Gross margin | n/a | n/a | 66.9% (computed) | n/a |
| Operating margin | n/a | -98.2% | -111.0% | n/a |
| Net margin | n/a | -101.1% | 10.8% | n/a |
| Net income | -$63.24M | -$50.34M | $6.82M | -$45.55M |
| EPS (Diluted) | -$2.19 | -$0.14 | -$0.07 | -$0.98 |
| Operating cash flow | -$51.77M | -$67.85M | -$65.78M | -$16.52M |
| Free cash flow | -$51.79M | -$67.85M | n/a | -$16.62M |
| Cash & equivalents | $176.48M | $34.33M | $79.38M | $179.97M |
| Total assets | $184.69M | $184.99M | $185.55M | $182.62M |
| Total liabilities | $33.55M | $77.45M | $123.36M | $5.61M |
| Shareholders' equity | $151.14M | $107.54M | $49.87M | $177.01M |
| Return on year-end equity | -41.8% | -46.8% | 13.7% | -25.7% |
| Shares outstanding | 31.92M | 365.85M | 31.36M | 34.42M |
Revenue, most recent five fiscal years
| Fiscal year | Alto Neuroscience, Inc. | Lexicon Pharmaceuticals, Inc. | Fortress Biotech, Inc. | Benitec Biopharma Inc. |
|---|---|---|---|---|
| Latest | n/a | $49.80M Ended 2025-12-31 | $63.26M Ended 2025-12-31 | $0 Ended 2024-06-30 |
| 1 year earlier | n/a | $31.08M Ended 2024-12-31 | $57.67M Ended 2024-12-31 | $75.0K Ended 2023-06-30 |
| 2 years earlier | n/a | $1.20M Ended 2023-12-31 | $84.51M Ended 2023-12-31 | $73.0K Ended 2022-06-30 |
| 3 years earlier | n/a | $139.0K Ended 2022-12-31 | $75.74M Ended 2022-12-31 | $59.0K Ended 2021-06-30 |
| 4 years earlier | n/a | $298.0K Ended 2021-12-31 | $68.79M Ended 2021-12-31 | $97.0K Ended 2020-06-30 |